Keun-Ho Ryu

This inventor holds 6 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Sk Chemicals Co., Ltd., Tiumbio Co., Ltd.. Active years: 2013-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keun-Ho Ryu. Retrieved from https://idiyas.com/inventor/keun-ho-ryu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 3)

% Patents Active = 33.3

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 7.3

ph-index = 2

Forward Citations = 6(Granted Patents)

Company Filing History:

5 out of 201

Sk Chemicals Co., Ltd.

Years Active: 2013-2018

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10155763 - 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors (2018-12-18),

2. 9271916 - Composition for reducing skin wrinkles including PDE5 inhibitor (2016-03-01),

3. 9168212 - Composition for eyelash growth (2015-10-27),

4. 9155691 - Composition for reducing skin wrinkles including PDE5 inhibitor (2015-10-13),

5. 8716298 - Composition for reducing skin wrinkles including PDE5 inhibitor (2014-05-06),

6. 8410146 - 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors (2013-04-02),

Title: Keun-Ho Ryu: Innovator in Pharmaceutical Chemistry

Introduction

Keun-Ho Ryu is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of six patents. His work focuses on developing innovative compounds that have potential therapeutic applications.

Latest Patents

One of his latest patents is for a novel 2-pyridyl substituted imidazole derivative, which selectively inhibits the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4). This invention provides a pharmaceutical composition that can be used for preventing or treating diseases mediated by these receptors in mammals. Another notable patent involves a composition effective in reducing skin wrinkles, which includes a phosphodiesterase 5 (PDE5) inhibitor, specifically mirodenafil, as an active ingredient. This composition offers a method for reducing skin wrinkles, showcasing Ryu's versatility in addressing both medical and cosmetic needs.

Career Highlights

Throughout his career, Keun-Ho Ryu has worked with notable companies such as SK Chemicals Co., Ltd. and Tiumbio Co., Ltd. His experience in these organizations has allowed him to refine his skills and contribute to various innovative projects in the pharmaceutical industry.

Collaborations

Ryu has collaborated with esteemed colleagues, including Bong-Yong Lee and Jae-Sun Kim. These partnerships have likely enhanced his research and development efforts, leading to successful innovations in his field.

Conclusion

Keun-Ho Ryu is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in therapeutic compounds. His patents reflect a commitment to innovation and improving health outcomes.

Profile summary based on public USPTO records.